Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Organisation › Details

Vedere Bio II Inc. (new, founded 10/20)

Vedere Bio II, which will be referred to as Vedere going forward, is a privately held, emerging biopharmaceutical company leveraging an ocular gene therapy toolbox to develop a pipeline of vision restoration and vision preservation therapies. Comprised of a diverse team of pioneering scientists, Vedere Bio II is discovering and developing next generation ocular gene therapies to make vision restoration a reality in areas of high global unmet medical need. The company is headquartered in Cambridge, MA and is funded by Atlas Venture, Mission BioCapital and Foundation Fighting Blindness (RD Fund). *

 

Period Start 2020-10-29 established (approx)
  Predecessor Vedere Bio Inc. (old, sold to Novartis 9/20)
Product Industry gene therapy eye disease
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 400 Technology Square
10th Floor
  City 02139 Cambridge, MA
  Tel +1-857-201-2700
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Vedere Bio, Inc.. (10/29/20). "Press Release: Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company". Cambridge, MA.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Vedere Bio II Inc. (new, founded 10/20)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top